Neuro endocrine tumor
Conditions
Interventions
Blood sampling schedule
• Whole blood will be collected at baseline (defined as prior to
SIRT/embolisation/ablative moment)
three base-line bloods.
• Blood samples before and 15 mins after each embolic or ablative event during
the course of the procedure and day 5.
• Whole blood collected at each patient visit for the du
Sponsors
Nederlands Kanker Instituut
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • >= 18 years old with metastatic well differentiated neuroendocrine tumor of gastro-enteropancreatic origin who will undergo a local ablative treatment or HAE/SIRT . • Patients have measurable disease • WHO performance status 0-2 • Life expectancy more than 3 months • Use of the standard embolization/RFA NET-NKI protocol
Exclusion criteria
Exclusion criteria: 1. Known history of HIV seropositivity. 2. contraindication for liverembolisation, RFA/MWA or SIRT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of hepatic metastatic embolization (HAE/SIRT) on PCR score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Determine whether blood PCR score correlates with metastasis burden 2) Determine whether ablation efficacy and PCR score correlate with assessment of tumor anatomical burden post-ablative imaging 3) Determine whether embolization/SIRT efficacy and PCR score correlate with tumor assessment anatomical burden post embolisation 4) Correlate residual tumor burden using functional tumor imaging with PCR score. 5) Evaluate stability/progression of tumor post ablation using PCR score vs. patient parameters and imaging. 6) Comparison of plasma CgA measurements with the PCR score, for the same. | — |
Countries
Netherlands
Outcome results
None listed